Maze Therapeutics: Atul Dandekar sells 7,500 shares

Atul Dandekar’s transactions were covered by a Rule 10b5-1 plan adopted September 29, 2025; his option award became fully vested on March 17, 2025.

Rhea-AI Filing Summary

Maze Therapeutics, Inc. CSBO Atul Dandekar exercised options covering 7,500 common shares on September 29, 2026, at an exercise price of $10.42 per share, and sold 7,500 shares that day at a weighted average price of $27.0561 per share. The sales occurred in multiple transactions priced from $26.47 to $27.45 per share. The transactions were made under a Rule 10b5-1 trading plan adopted September 29, 2025. The option award was fully vested on March 17, 2025, and 6,643 option shares remained after the exercise.

Insider Trade Summary 10b5-1

Exercise and Sale: 7,500 shares ($125K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Dandekar Atul

Role CSBO

Sold 7,500 shs ($203K)

Approx. gross sale proceeds $203K

Approx. exercise cost $78K

Approx. pre-tax spread $125K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F3	7,500	$0.00	$0.00
Exercise	Common Stock F1	7,500	$10.42	$78K
Sale	Common Stock F1, F2	7,500	$27.0561	$203K

Holdings After Transaction: Stock Option (Right to Buy) — 6,643 contracts (Direct); Common Stock — 32,316 shares (Direct)

Footnotes (3)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.47 to $27.45 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.

Key Figures

Options exercised: 7,500 shares Exercise price: $10.42 per share Shares sold: 7,500 shares +3 more

6 metrics

Options exercised 7,500 shares September 29, 2026

Exercise price $10.42 per share Options exercised September 29, 2026

Shares sold 7,500 shares September 29, 2026

Weighted average sale price $27.0561 per share Sale on September 29, 2026

Sale price range $26.47 to $27.45 per share Prices in multiple sale transactions

Option shares remaining 6,643 shares Following the September 29, 2026 exercise

Key Terms

Rule 10b5-1 trading plan, weighted average price, exercise price, fully vested

4 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"reported price in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

exercise price financial

"at an exercise price of $10.42 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

fully vested financial

"The option is fully vested"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MAZE shares did Atul Dandekar sell, and at what price?

Atul Dandekar sold 7,500 MAZE shares on September 29, 2026, at a weighted average price of $27.0561 per share. The sales took place in multiple transactions at prices from $26.47 to $27.45 per share and were made under a Rule 10b5-1 plan adopted September 29, 2025.

What were the terms of Atul Dandekar’s MAZE option exercise?

Atul Dandekar exercised options covering 7,500 common shares on September 29, 2026, at an exercise price of $10.42 per share. The option award had become fully vested on March 17, 2025, and 6,643 option shares remained after the exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/01/2026 - 04:07 PM Accepted by SEC EDGAR 10/01/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dandekar Atul

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CSBO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/29/2026		M(1)		7,500	A	$10.42	39,816	D
Common Stock	09/29/2026		S(1)		7,500	D	$27.0561(2)	32,316	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.42	09/29/2026		M(1)			7,500	(3)	04/11/2031	Common Stock	7,500	$0	6,643	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.47 to $27.45 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.

	/s/ Courtney Phillips, as attorney-in-fact	10/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)